Intech Investment Management LLC Acquires New Holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Intech Investment Management LLC bought a new position in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 12,714 shares of the company’s stock, valued at approximately $74,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Victory Capital Management Inc. boosted its holdings in Voyager Therapeutics by 14.5% during the second quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock worth $102,000 after buying an additional 1,630 shares in the last quarter. SummerHaven Investment Management LLC lifted its position in shares of Voyager Therapeutics by 2.5% during the 2nd quarter. SummerHaven Investment Management LLC now owns 77,293 shares of the company’s stock valued at $611,000 after acquiring an additional 1,921 shares during the last quarter. Hunter Perkins Capital Management LLC grew its holdings in shares of Voyager Therapeutics by 3.3% in the 3rd quarter. Hunter Perkins Capital Management LLC now owns 64,040 shares of the company’s stock worth $375,000 after acquiring an additional 2,025 shares during the last quarter. Empowered Funds LLC boosted its position in shares of Voyager Therapeutics by 5.4% in the 3rd quarter. Empowered Funds LLC now owns 44,809 shares of the company’s stock valued at $262,000 after purchasing an additional 2,278 shares during the period. Finally, Federated Hermes Inc. increased its stake in Voyager Therapeutics by 0.5% in the 2nd quarter. Federated Hermes Inc. now owns 554,214 shares of the company’s stock worth $4,384,000 after purchasing an additional 2,638 shares in the last quarter. 48.03% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have commented on VYGR. Leerink Partnrs raised shares of Voyager Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 16th. Canaccord Genuity Group reissued a “buy” rating and issued a $14.00 price objective on shares of Voyager Therapeutics in a research note on Thursday, November 14th. HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Voyager Therapeutics in a research report on Thursday, November 14th. Citigroup initiated coverage on Voyager Therapeutics in a report on Monday, December 2nd. They issued a “buy” rating and a $12.00 target price on the stock. Finally, Leerink Partners started coverage on shares of Voyager Therapeutics in a research note on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 price objective on the stock. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Voyager Therapeutics has a consensus rating of “Buy” and an average price target of $17.00.

Voyager Therapeutics Price Performance

Voyager Therapeutics stock opened at $6.45 on Monday. Voyager Therapeutics, Inc. has a one year low of $5.19 and a one year high of $11.72. The company’s fifty day moving average price is $6.57 and its two-hundred day moving average price is $7.22. The company has a market capitalization of $352.34 million, a price-to-earnings ratio of 9.08 and a beta of 0.90.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.29. The business had revenue of $24.63 million for the quarter, compared to analyst estimates of $12.63 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. During the same quarter in the prior year, the firm posted ($0.59) EPS. As a group, sell-side analysts anticipate that Voyager Therapeutics, Inc. will post -0.89 earnings per share for the current year.

Insider Transactions at Voyager Therapeutics

In related news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the business’s stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total transaction of $34,914.18. Following the transaction, the insider now owns 86,001 shares of the company’s stock, valued at approximately $500,525.82. The trade was a 6.52 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 4.53% of the stock is owned by corporate insiders.

Voyager Therapeutics Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.